2021-2022 Annual Report

Welcome to interactive presentation, created with Publuu. Enjoy the reading!

2020 • 21

ANNUAL

REPORT

PhARMprogram.org

2021 - 2022

@PhARMprogram

MEET THE TEAM

Lucas G. Hill

PharmD, BCACP

Director & Lead Instructor

Carlos F. Tirado

MD, MPH, FASAM

Medical Consultant &

Clinical Instructor

Claire Zagorski

MSc, LP

Coordinator & Harm

Reduction Instructor

Ms. Zagorski earned a Bachelor’s Degree at The University of

Texas at Austin and a Master’s Degree at The University of North

Texas Health Science Center. She has practiced clinically as a

paramedic in multiple treatment settings, including as a member of

the Austin Harm Reduction Coalition. She founded Longhorn Stop

the Bleed and is committed to supporting healthcare professionals

who seek to integrate harm reduction principles in their practice.

Dr. Hill graduated from the UMKC School of Pharmacy and

completed a combined residency/fellowship in the UPMC

Department of Family Medicine. He is now a clinical associate

professor at The University of Texas at Austin College of Pharmacy

where he founded the PhARM Program and Operation Naloxone.

Dr. Hill is the principal investigator for a five-year $25 million TTOR

contract to address the opioid crisis in Texas. He also serves on

the editorial board of JACCP and as past chair of the AACP SUD

Special Interest Group.

Lindsey J. Loera

PharmD

Research Fellow

Dr. Loera graduated from UT Austin College of Pharmacy in 2020

and is completing a two-year fellowship with the PhARM Program.

She conducts research related to the pharmacists’ role in substance

use disorder treatment and harm reduction and provides instruction

in pharmacotherapy and interprofessional collaboration courses.

Dr. Loera is a past President of the Student Pharmacist Recovery

Network and co-founded the P4 Addiction Medicine APPE at UT.

Dr. Tirado earned his MD and MPH degrees at UT Health,

completed a residency in psychiatry at UT Southwestern, and

completed a fellowship in addiction psychiatry at the University

of Pennsylvania. He is board-certified in general and addiction

psychiatry, and he is the founder and chief medical officer of

CARMAhealth – a primary care medical home for people with

substance use and psychiatric disorders.

2022-2023 RESEARCH ASSISTANTS

Amber Tran

Amber is a rising third-year pharmacy student who attended UT Austin for undergrad

where she earned a BS in Psychology. She is interested in interactions between biological,

psychological, and social factors that contribute to health outcomes. She has a passion

for mental health advocacy, reducing health disparities to promote health equity, and

hopes to pursue a career in psychiatric pharmacy.

Kami Johnston

Kami is a P4 student and is

the current student director

of Operation Naloxone.

Her primary research project

included delivering and

evaluating the impact of

interprofessional overdose

response education for health

professions students.

Morgan is a P4 student and

CPNP member. Her primary

research project included

interviewing the directors of

professional recovery programs

in Texas to describe their

policies related to medications

for opioid use disorder.

Morgan Murchison

Chandler Prevatt

Chandler is a former PharmD

student and the Founder and

Lead Developer of ELIFT

Creations. She built the

PhARMprogram.org website

and this annual report! She is

passionate about providing

community organizations with

the tools they need to advance

their goals.

Megan is a P4 student and

peer outreach chair for CPNP.

Her primary research project

focused on assessing the

availability of buprenorphine-

naloxone and naloxone nasal

spray in Harris County, TX and

Philadelphia County, PA.

Megan Yeung

2021-2022 RESEARCH ASSISTANTS

Grace Ukazim

Grace is a rising third-year pharmacy student at UTCOP. She is a pharmacist intern

at H-E-B Pharmacy and serves as treasurer and president-elect of SNPhA. She is

passionate about serving the underserved and looks forward to learning more about

addiction medicine and ways to positively impact healthcare.

TEXAS TARGETED OPIOID RESPONSE

The Texas Opioid Training Initiative at TXOTI.org is the hub for opioid-related

continuing education and clinical resources developed by our team with support from

the Texas Targeted Opioid Response. We owe special thanks to the UT Center for

Health Communication for web design and to UT Continuing Pharmacy Education for

facilitating development of free online CE programs – 17 hours and counting!

10,710

Pharmacists

579 physicians

510 advanced practice providers

324 social workers

227 nurses

170 counselorsph

97 peer recovery specialists

530 other

13,147 professionals have completed TXOTI CE programs in the past year alone!

We were honored to partner with Dr. Jennifer Potter and Be Well, Texas to

host the first in-person Texas Substance Use Symposium (TxSUS). TxSUS

was a remarkable success with 278 live attendees in Corpus Christi and 116

virtual attendees. Recorded plenaries from national and regional experts will

be available for free CE at TxSUS.org in June. Keep an eye on the website and

mark your calendar for TxSUS 2023 in San Antonio on March 27th and 28th!

Top Left: Jennifer Potter moderates the opening expert panel / Top Right: Texas Harm Reduction Alliance leads a workshop

Bottom Left: TxSUS attendees observe a plenary session / Bottom Right: Sunset in Corpus Christi, TX

NATIONAL RECOGNITION

Hill LG, Loera LJ, Evoy KE, Torrez SB, Renfro ML, Zagorski CM, Perez JC, Jones SM, Reveles KR. Availability of buprenorphine/naloxone films

and naloxone nasal spray in community pharmacies in Texas, United States. Addiction. DOI: 10.1111/ADD.15314

Most Texas pharmacies are not prepared to dispense

buprenorphine/naloxone films & naloxone nasal spray

704 pharmacies audited

471 chains

233 independents

A cross-sectional telephone audit with a secret shopper approach conducted in Spring 2020

Availability & willingness

to order were higher in

chains vs independents

34.1% reported availability of both

medications for prompt dispensing

62.2% without BUP/NX available

were willing to order it (M = 2 days)

60.1%

42.2%

39.9%

57.8%

BUP/NX

& NNS

Available

Willing to

Order

BUP/NX

45.0%

73.9%

12.0%

48.0%

BUP/NX 8/2mg

generic #14 films

NNS 4mg

brand #1 box

The American College of Clinical Pharmacy recently bestowed

the prestigious New Educator Award to Dr. Hill. Our team also

received the Ambulatory Care PRN Outstanding Paper Award for

our publication in Addiction, and Dr. Loera was recognized with

the Research Fellow Best Poster Award for an expansion of that

study in ten other U.S. states.

OPERATION NALOXONE

Operation Naloxone is an interprofessional collaboration led by student pharmacists

that provides overdose education and naloxone distribution on campus. Since 2016,

Operation Naloxone has trained 1,733 community members and distributed 1,518 doses

of naloxone!

To further enhance naloxone access on the UT Austin campus, Kami

Johnston and Claire Zagorski collaborated with faculty and staff across

the university to facilitate availability in campus libraries. Since February

2022, naloxone has been available for pickup at the Perry-Castañeda

Library, and for emergency access at the Life Sciences Library and Benson

Library. We owe particular gratitude to Geoff Bahre for championing

this initiative within UT Libraries and to UT SHIFT for providing the funds

to purchase naloxone.

312

Implementing access in UT Libraries led

to distribution of 312 naloxone doses!

PHARMD EDUCATION

The University of Texas at Austin College of Pharmacy provides 23.5 hours of required

didactic instruction related to substance use disorder and harm reduction. Education is a

key component to broadening perspectives and altering beliefs toward people who use

drugs, and it is crucial for PharmD curricula to support the development of our students

and profession in this domain. Megan, Kami, and Morgan recently led development of

a blog post describing our curriculum, and it has been accepted for publication in Pulses.

New Student Orientation

1.5 hours

• Opioid overdose education &

naloxone distribution training

Foundations of Interprofessional

Collaborative Practice

3 hours

• Screening, brief intervention and

referral to treatment simulation

Pathophysiology

1 hour

• Substance use disorder

pathophysiology lecture

Clinical Skills Lab

2 hours

• Addressing substance use at

the pharmacy counter lecture

• Opioid overdose education

& naloxone distribution

simulation

Nonprescription

Pharmacotherapeutics

5 hours

• Tobacco use disorder lecture

and simulation

Pharmacotherapy of Addiction

11 hours

• Substance use disorders

• Opioid use disorder

• Alcohol use disorder

• Tobacco use disorder

• Intoxication

• Withdrawal

• Stimulant and sedative use

disorder

• Harm reduction

• Behavioral therapies for

substance use disorders

• Management of co-occurring

disorders

• Substance use disorder complex

case review

Addiction Medicine Elective APPE

250 hours

P1

5.5 hours

P2

7 hours

P3

11 hours

P4

250 hours (optional)

Operation Naloxone IPPE Events

2 hours per semester (optional)

ENDOWED LECTURE

Dr. Dasgupta and Ms. Figgatt discussed an

innovative drug checking service developed

by the Opioid Data Lab to inform North

Carolina’s public health response to

substance use challenges. Dr. Dasgupta is an

applied epidemiologist, an associate editor

for the American Journal of Public Health, and

the founder of Project Lazarus. Ms. Figgatt

is a PhD candidate in epidemiology and

implemented Philadelphia’s drug overdose

fatality review program. A recording of this

lecture is available on the events page of

our website.

We extend special thanks to Dean Poloyac for supporting this lecture and other critical PhARM

Program activities through the Bergen Brunswig Corporation Centennial Endowed Fellowship.

Mary Figgat instructing Kasey Claborn (Assistant Professor, Steve Hicks School of Social

Work) to collect and package a sample for testing

Nabarun Dasgupta providing historical perspective on opioid manufacturing and testing

Chandler Prevatt recently

transitioned

from

a

research assistant role to

become our digital content

manager. She created our

outstanding new website

and this annual report! Visit

eliftcreations.com to see

more of Chandler’s work, and hire her to build

your next website.

Sorina Torrez served as

one of the first PhARM

Program research assistants

in 2020–2021, and she will

rejoin us in Summer 2022

as she pursues a MS in

pharmaceutical science.

Sorina will complete clinical

rotations throughout Central Texas and plans to focus

her research on implementation of SUD treatment in

community pharmacies.

In addition to serving as

our Program Coordinator,

Claire is an accomplished

scholar in peer-reviewed

and popular media. In

2020, she was the lead

author for a viewpoint in

Int J Drug Policy exploring

the dangers of isotonitazene. Claire is also well

known for her Etsy Shop featuring high-quality

pins and stickers with harm reduction messaging.

In Summer 2022, Claire will begin completing a

PhD in translational science. She plans to focus her

research on implementation and evaluation of a

low-barrier methadone program.

As the inaugural PhARM

Fellow, and coiner of the

PhARM acronym, Dr. Loera

has been central to our

program’s recent success.

Since 2019, she has

authored six peer-reviewed

manuscripts and 34 peer-

reviewed posters. She has also been recognized

with prestigious research awards from ACCP, AACP,

and UTCOP. In 2022, Dr. Loera was the lead author

for a research brief in Am J Pharm Educ describing

the Addiction Medicine APPE that she created. She

will continue her career in a faculty role at UTCOP

beginning Fall 2022!

STAFF TRANSITIONS

Lindsey J. Loera, PharmD

Claire Zagorski, MSc, LP

Chandler Prevatt , B.S.

Sorina Torrez, PharmD

99

STAFF SPOTLIGHT

PUBLICATIONS

1. Loera LJ, Hill LG, Zagorski CM, Jermain ML, Tirado CF. (2022). Description and evaluation of a pilot

advanced pharmacy practice experience in addiction medicine. Am J Pharm Educ. 8926.

2. Gugala E, Briggs O, Moczygemba LR, Brown CM, Hill LG. (2022). Opioid harm reduction: A

scoping review of physician and system-level gaps in knowledge, education, and practice. Subst Abus.

43(1):972-987.

3. White KM, Hill LG, Perez JC, Torrez SB, Zagorski CM, Loera LJ. (2022). Policies regarding use of

medications for opioid use disorder in professional recovery programs: A scoping review. Subst Abus.

43(1):749-755.

4. Hill LG, Zagorski CM, Loera LJ. (2022). Increasingly powerful opioid antagonists are not necessary.

Int J Drug Policy. 99:103457.

5. Hill LG, Loera LJ, Evoy KE, Torrez SB, Renfro ML, Zagorski CM, Perez JC, Jones SM, Reveles KR. (2021).

Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in

Texas, USA. Addiction. 116(6):1505-1511.

6. Bottner R, Weems J, Hill LG, Ziebell C, Long S, Young S, Sasser M, Ferguson A, Tirado C. (2021).

Addiction treatment networks cannot withstand acute crises: Lessons from Winter Storm Uri in Texas.

NAM Perspectives.

7. Peckham AM, Ball J, Colvard MD, Dadiomov D, Hill LG, Nichols SD, Tallian K, Ventricelli DJ, Tran TH.

(2021). Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder

amid COVID-19 pandemic. Am J Health Syst Pharm. 78(7):612-618.

8. Evoy KE, Hill LG, Davis CS. (2021). Considering the potential benefits of over-the-counter naloxone.

Integr Pharm Res Pract. 10:13-21.

9. Coon SA, Hill LG, Hutchison RW, et al. (2020). Mobilizing pharmacists to address the opioid crisis:

A joint opinion of the ambulatory care and adult medicine practice and research networks for the

American College of Clinical Pharmacy. J Am Coll Clin Pharm. 3(8):1493-1513.

10. Tran T, Ball J, Bratberg JP, DeSimone EM, Franko TS, Hill LG, Koh-Knox Sharp CP, Palombi L, Ventricelli

D, Farrell D, Gandhi N, Moore T. (2020). Report of the 2020 special committee on substance use and

pharmacy education. Am J Pharm Educ. 84(11):8421.

11. Litten K, Hill LG, Garza A, Srinivasa M. (2020). Increasing naloxone knowledge and use through

direct-to-patient education. J Pharm Technol. 36(6):237-242.

12. Renfro ML, Moczygemba LR, Baumgartner J, Baumgart G, Hill LG. (2020). Opioid-related education

provided by continuing education divisions at US pharmacy schools. Am J Pharm Educ. 84(10):8001.

13. Renfro ML, Loera LJ, Tirado CF, Hill LG. (2020). Lofexidine for acute opioid withdrawal: A clinical

case series. Ment Health Clin. 10(5):259-263.

14. Zagorski CM, Myslinski JM, Hill LG. (2020). Isotonitazene as a contaminant of concern in the illegal

opioid supply: A practical synthesis and cost perspective. Int J Drug Policy. 86:102939.

10

HIGHLIGHTED POSTERS

Non-Cognitive Predictors of Student Success:

A Predictive Validity Comparison Between Domestic and International Students

Description and Evaluation of

a Novel Advanced Pharmacy

Practice Experience (APPE)

in Addiction Medicine

BACKGROUND

●The U.S. faces a substantial burden of societal

harms related to substance use disorders (SUD)

●The 2019 AACP environmental scan identified a

concerning shortage of APPEs in this domain

●Addressing this deficit is essential to ensure

pharmacists are prepared to provide optimal care

●In Summer 2019, the University of Texas at Austin

College of Pharmacy began offering an elective

APPE in addiction medicine

APPE DESCRIPTION

ASSESSMENT METHODS

A 62-item assessment was administered to Summer

2020 students (n=3). The assessment had 51 items to

assess knowledge (47 short answer, 4 multiple choice)

and 11 Likert-scale items to assess confidence.

ASSESSMENT RESULTS

*p=.007

CONCLUSIONS

U.S. colleges of pharmacy that do not yet offer APPEs in

this clinical domain should consider this model.

Lindsey J. Loera, PharmD, RPh

Carlos F. Tirado, MD, MPH, FASAM

Claire M. Zagorski, MSc, LP

Lucas G. Hill, PharmD, BCPS, BCACP

Dr. Tirado has served as a consultant for Alkermes, Inc and US

World Meds, LLC. Dr. Hill has served on the Hikma Speciality Inc.

Community Advisory Board in December 2020. No other authors

have any potential conflicts of interest or funding to report.

A pilot APPE in addiction

medicine addressed a

current gap in pharmacy

education, earned

positive evaluations from

students, and increased

SUD-related knowledge

and confidence.

Pre/Post-APPE Assessment

Neurobiology

Opioid use disorder

Alcohol use disorder

Stimulant use disorder

Tobacco use disorder

Harm reduction

Depression/anxiety

Bipolar disorder

Schizophrenia

10

Sleep disorder

Change in Cumulative Knowledge Scores

Overall*

Student 1 Student 2 Student 3

Pre

Post

Change in Cumulative Confidence Scores

Overall*

Student 1 Student 2 Student 3

“This APPE strengthened an idea that I will carry through

my career: there is hope for every disease state. I want to

be that hope.”

“The insight from this APPE will help me tremendously in

the future to better serve patients who are in recovery.”

“I loved educating patients about their medications

because I always learned something. I feel I will be able

to advocate for patients with SUD in the future and refer

them to appropriate care.”

Free Text Responses from Students

250-260 hours

over 6 weeks

4 Medication Education

Groups with Clients

1 Journal Club

1 Topic Discussion

1 Case Presentation

1 Research Project

Per Student

4 Practice Sites

100

75

50

25

100

75

50

25

●Outpatient medical home

for SUD and psychiatric

disorders

●90-day residential program

●SUD treatment center

(detox, residential,

outpatient)

●Opioid treatment program

Low

Low - Mod

Mod - High

High

60

40

20

0

Low

Low - Mod

Mod - High

High

60

40

20

0

Medication, n (%)

Harris County

Philadelphia County

BUP/NX

47 (19.0)

42 (38.5)

NNS

100 (40.3)

31 (28.4)

Figure 1. Availability of BUP/NX

Figure 2. Availability of NNS

Buprenorphine/naloxone film and naloxone nasal spray pharmacy deserts in

Harris County, Texas and Philadelphia County, Pennsylvania

Persons with opioid use disorder (OUD) must be

able to obtain buprenorphine/naloxone films

(BUP/NX) and naloxone nasal spray (NNS) in a

timely manner to reduce the risk for recurrence of

use, morbidity, and mortality

This study was a focused assessment in two highly

populated and demographically diverse counties

Background

Results

Methods

300 pharmacies

130 pharmacies

Telephone audit conducted from 4/1/2021 to

9/30/2021

Primary outcomes included availability of a one-

week supply of generic BUP/NX 8/2mg and a single

unit of NNS

Secondary outcomes included willingness to order

BUP/NX if unavailable and estimated timeframe

Pharmacies were excluded if unreachable after

three attempts, refused to disclose information, or

were not a community pharmacy

% of Pharmacies

Harris County, n=248

Philadelphia County, n=106

Few pharmacies in these metropolitan counties are

prepared to dispense BUP/NX and NNS, with greater

deficiencies in independent pharmacies.

Conclusions

Medication Availability by Social

Vulnerability Index

BUP/NX

NNS

% of Pharmacies

62

36

58

92

18

31

51

1. The University of Texas at Austin, Austin, TX; 2. The George

Washington University, Washington, D.C.; 3. University of the

Sciences Philadelphia, Philadelphia, Pennsylvania

Megan S. Yeung, PharmDc 2023 ; Lindsey J. Loera, PharmD ; Margaret R. Peterson, MSc ; Morgan L. Murchison, PharmDc 2023 ; Kami E.

Johnston, PharmDc 2023 ; Chandler A. Prevatt ; Andrew M. Peterson, PharmD, PhD ; Kelly R. Reveles, PharmD, PhD ; Lucas G. Hill, PharmD

Medication Availability by County

11

Non-Cognitive Predictors of Student Success:

A Predictive Validity Comparison Between Domestic and International Students

Non-Cognitive Predictors of Student Success:

A Predictive Validity Comparison Between Domestic and International Students

A qualitative report of fentanyl

exposure among people who use

drugs in Austin, Texas

BACKGROUND

●Black tar heroin is a tacky, tar-like substance

●From Nov 2020 to Oct 2021, the CDC reported overdose deaths

due to synthetic opioids increased in Texas by 70%

●Little is known about the emergence of fentanyl in states where

black tar heroin predominates

OBJECTIVE

To describe fentanyl exposure, methods of fentanyl identification,

and harm reduction practices among people who use opioids

METHODS

Interviews conducted July 16-23, 2021 of 30 clients

accessing harm reduction services at two mobile

outreach syringe services programs in Austin, TX

Clients reported heroin or fentanyl use within the prior

week

Responses were analyzed using a deductive (via NVivo

12.0) and inductive hybrid approach

CONCLUSIONS

The emergence of fentanyl exposure despite the predominance of

black tar heroin calls for public health initiatives that aim to

reduce associated harms for people who use drugs

This project is supported by Texas Targeted Opioid Response, a public health initiative operated by

the Texas Health and Human Services Commission through federal funding from the Substance

Abuse and Mental Health Services Administration grant award number H79TI083288

RESULTS

Participant Characteristics

Emerging Themes

Methods of Fentanyl Identification

Harm Reduction Recommendations

Sorina B. Torrez, PharmDc 20221 | sorinatorrez@utexas.edu

Austin Buck, PharmDc 20221; Lindsey J. Loera, PharmD1; Claire M. Zagorski, MSc1; Jessica D. Cance,

MPH, PhD2; Amanda Bingaman2; Heather Kane, PhD2; Sara Hairgrove2; Lucas G. Hill, PharmD1.

1. The University of Texas at Austin, Austin, TX. 2. RTI International, Research Triangle Park, NC.

Increased exposure to fentanyl

Methods of detecting and identifying fentanyl

Harm reduction strategies to mitigate risks

56.7% male, 33.3% female, 10% nonbinary

41.7 years median age

66.7% unhoused or in transitional living

50% Caucasian

Use of fentanyl strips

Physical inspection

Experiencing increased effects

Use of fentanyl test stips

Try a smaller amount first

Keep naloxone on hand

People who use opioids

in Austin, TX report

increased exposure to

fentanyl and related

adverse events despite

regional predominance of

black tar heroin

“I’m pretty much always

using fentanyl because

they’re putting it in…

everything now”

“They’ll sell it as

heroin, but it’s not

heroin…”

Availability of buprenorphine/naloxone

films and naloxone nasal spray in

community pharmacies in eleven U.S.

states

INTRODUCTION

Patients with opioid use disorder must be able to obtain

prescribed buprenorphine/naloxone films and naloxone nasal

spray from a community pharmacy promptly to reduce a risk for

recurrence of use and subsequent morbidity and mortality

STUDY QUESTION

Are community pharmacies in 11 U.S. states prepared to

promptly dispense buprenorphine/naloxone films and naloxone

nasal spray?

STUDY DESIGN

●Telephone audit conducted May 2020 to May 2021

●5734 randomly selected pharmacies in eleven U.S. states

●States: AZ, CA, FL, MA, ME, ND, NJ, OH, PA, SD, TX

METHODS

●BUP/NX: #14 generic buprenorphine/naloxone films

●NNS: a single unit of branded naloxone nasal spray

●Assessed availability of each medication, as well as

willingness and timeframe to order the buprenorphine

product

●Compared by pharmacy type, county metropolitan status,

state Medicaid expansion status, and state drug overdose

death rate

CONCLUSIONS

BUP/NX and NNS are not readily available in many U.S.

pharmacies, demonstrating a barrier to timely access of these

vital medications. Deficits are most pronounced in independent

pharmacies, states that have not expanded Medicaid, and states

with relatively low drug overdose rates.

Contact Information: Lindsey J. Loera, PharmD

lindsey.loera@austin.utexas.edu | @TheSUDPharmD

1. The University of Texas at Austin College of Pharmacy 2. KGI School of Pharmacy and Health Sciences 3. University of the Sciences Philadelphia College of Pharmacy 4. North Dakota State University

School of Pharmacy 5. Massachusetts General Hospital Substance Use Disorders Initiative 6. Rutgers New Jersey Medical School 7. Cooper University Healthcare Division of Addiction Medicine

Lindsey J. Loera1, Lucas G. Hill1, Sorina B. Torrez1, Talia Puzantian2, Daniel J.

Ventricelli3, Heidi N. Eukel4, Kirk E. Evoy1, Alyssa M. Peckham5, Clement Chen6,

Valerie S. Ganetsky7, Megan Yeung1, Claire M. Zagorski1, Kelly R. Reveles1

Medication

Metro

(n=4431)

Non-Metro

(n=553)

P-value

High OD

(n=3163)

Low OD

(n=1821)

P-value

Expansion

(n=3448)

Non-Expansion

(n=1536)

P-value

BUP/NX + NNS

1816 (41.0)

238 (43.0)

0.3557

1489 (47.1)

565 (31.0)

<0.0001

1579 (45.8)

475 (30.9)

<0.0001

BUP/NX

2096 (47.3)

310 (56.1)

0.0001

1710 (54.1)

696 (38.2)

<0.0001

1828 (53.0)

578 (37.6)

<0.0001

NNS

3122 (70.5)

344 (62.2)

<0.0001

2383 (75.3)

1083 (59.5)

<0.0001

2503 (72.6)

963 (62.7)

<0.0001

2 Days

Median Order Time for BUP/NX

64.0% of pharmacies that did

not have BUP/NX available

were willing to order it

0%

20%

40%

60%

80%

100%

All (n=4984)

ME (n=174)

MA (n=350)

OH (n=361)

AZ (n=366)

ND (n=149)

PA (n=689)

NJ (n=540)

TX (n=704)

SD (n=149)

FL (n=683)

CA (n=819)

Availability of BUP/NX

Overall

Chain

Independent

0%

20%

40%

60%

80%

100%

All (n=4984)

MA (n=350)

ME (n=174)

AZ (n=366)

PA (n=689)

OH (n=361)

FL (n=683)

NJ (n=540)

CA (n=819)

TX (n=704)

ND (n=149)

SD (n=149)

Availability of NNS

12

1. Yeung M, Loera LJ, Peterson MR, Murchison ML, Johnston KE, Prevatt CA, Peterson AM, Reveles KR, Hill

LG. Buprenorphine/naloxone film and naloxone nasal spray pharmacy deserts in Harris County, Texas and

Philadelphia County, Pennsylvania. College of Psychiatric & Neurologic Pharmacists Annual Meeting; April

2022.

2. Torrez SB, Buck A, Zagorski CM, Loera LJ, Cance JD, Bingaman A, Kane H, Hairgrove S, Hill LG. A

qualitative report of fentanyl exposure among people who use drugs in Austin, Texas. College of Psychiatric

& Neurologic Pharmacists Annual Meeting; April 2022.

3. Buck A, Bird J, Tirado CF, Loera LJ, Hill LG. Analysis of clinical characteristics of Travis County patients in

a Central Texas outpatient substance use clinic. American Society of Health-System Pharmacists Midyear

Clinical Meeting; December 2021.

4. Houser E, Bicker AM, Torrez SB, Loera LJ, Hill LG. Availability of buprenorphine/naloxone films and

naloxone nasal spray in community pharmacies in Arizona. American Society of Health-System Pharmacists

Midyear Clinical Meeting; December 2021.

5. Pac W, Haley A, Nieman M, Notarianni V, Son D, Roy S, Ventricelli DJ, Torrez SB, Loera LJ, Hill LG.

Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Pennsylvania.

American Society of Health-System Pharmacists Midyear Clinical

Meeting; December 2021.

6. Puzantian T, Karapetyan N, Safari MJ, Shaw BA, Singh S, Bokhari F, Reveles KR, Torrez SB, Loera LJ, Hill

LG. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in

California. Association for Multidisciplinary Education and Research in Substance Use and Addiction Annual

Meeting; November 2021.

7. Torrez SB, Perez JC, White KM, Loera LJ, Reveles KR, Evoy KE, Zagorski C, Bird J, Buck A, Burgess M, Charles

A, Gonzalez G, Tran A, Wijeratne A, Yeung M, Ukazim G, Nguyen N, Clague M, Hill LG. Availability of

buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Florida. Association for

Multidisciplinary Education and Research in Substance Use and Addiction Annual Meeting; November 2021.

8. Perez JC, Torrez SB, White KM, Loera LJ, Reveles KR, Evoy KE, Hill LG. Availability of buprenorphine/naloxone

films and naloxone nasal spray in community pharmacies in South Dakota. Association for Multidisciplinary

Education and Research in Substance Use and Addiction Annual Meeting; November 2021.

9. Loera LJ, Hill LG, Torrez SB, Puzantian T, Ventricelli DJ, Eukel HN, Evoy KE, Peckham AM, Chen C, Ganetsky

VS, Yeung M, Zagorski CM, Reveles KR. Availability of buprenorphine/naloxone films and naloxone nasal

spray in community pharmacies in eleven U.S. states. American College of Clinical Pharmacy Annual Meeting;

October 2021. Research Fellowship Best Poster.

13

PEER REVIEWED NATIONAL POSTERS

10. Loera LJ, Tirado CF, Zagorski CM, Hill LG. Description and evaluation of a novel advanced pharmacy

practice experience in addiction medicine. American Association of Colleges of Pharmacy Annual Meeting;

July 2021. Finalist – Best Poster by a Resident, Fellow, or Postdoc.

11. Vogt CM, Burgess MM, Charles AN, Loera LJ, Tirado CF, Hill LG. Analysis of patient-reported

satisfaction with long-acting injectables for opioid and alcohol use disorder in a Central Texas outpatient

clinic. College of Psychiatric & Neurologic Pharmacists Annual Meeting; April 2021.

12. Loera LJ, Hill LG, Zagorski CM, Castleberry AN. Analysis of student pharmacists’ intention to provide

harm reduction resources after brief education and a simulated patient encounter. College of Psychiatric

& Neurologic Pharmacists Annual Meeting; April 2021.

13. White KM, Hill LG, Perez JC, Torrez SB, Zagorski CM, Loera LJ. A scoping review of policies regarding

use of medications for opioid use disorder in professional recovery programs. College of Psychiatric &

Neurologic Pharmacists Annual Meeting; April 2021.

14. Nicholson MA, Patel RY, Solis JA, Evoy KE, Reveles KR, Torrez SB, Loera LJ, Hill LG. Maintaining

momentum on the road to recovery: availability of buprenorphine/naloxone films and naloxone nasal

spray in community pharmacies in Ohio. American Society of Health-System Pharmacists Midyear Clinical

Meeting; December 2020.

15. Burgess MM, Charles A, Vogt C, Reveles KR, Evoy KE, Torrez SB, Loera LJ, Hill LG. Maintaining

momentum on the road to recovery: availability of buprenorphine/naloxone films and naloxone nasal

spray in community pharmacies in Massachusetts. American Society of Health-System Pharmacists Midyear

Clinical Meeting; December 2020.

16. Charles A, Burgess MM, Vogt C, Reveles KR, Evoy KE, Torrez SB, Loera LJ, Hill LG. Maintaining

momentum on the road to recovery: availability of buprenorphine/naloxone films and naloxone nasal

spray in community pharmacies in Maine. American Society of Health-System Pharmacists Midyear

Clinical Meeting; December 2020.

17. Hill LG, Torrez SB, Loera LJ, Renfro ML, Reveles KR, Evoy KE. Assessing the availability of buprenorphine/

naloxone in pharmacies via telephone audit: A feasibility pilot. Association for Multidisciplinary Education

and Research in Substance Use and Addiction Annual Meeting; Boston, MA; November 2020.

18. Loera LJ, Renfro ML, Tirado CF, Hill LG. Description of a novel advanced pharmacy practice experience

in addiction medicine. College of Psychiatric and Neurologic Pharmacists Annual Meeting; Dallas, TX;

March 2020.

19. Renfro ML, Loera LJ, Tirado CF, Hill LG. Lofexidine for acute opioid withdrawal: A clinical case series.

College of Psychiatric and Neurologic Pharmacists Annual Meeting; Dallas, TX; March 2020.

14

G E T I N TO U C H

2409 University Avenue, A1910, PHR 2.222, Austin, TX 78712

PhARMprogram@austin.utexas.edu

@PhARMprogram

PhARMprogram.org

Special thanks to these collaborators!

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Made with Publuu - flipbook maker